Neurocrine Biosciences Unveils CEO Succession Plan

SAN DIEGO, May 28, 2024 — Neurocrine Biosciences, Inc. has announced a significant change in its executive leadership. Kevin Gorman, Ph.D., will retire from his role as Chief Executive Officer on October 11, 2024. Succeeding him will be Kyle Gano, Ph.D., who currently serves as the company’s Chief Business Development and Strategy Officer. Upon assuming the CEO position, Dr. Gano will also join the Board of Directors. Dr. Gorman, who founded Neurocrine in 1992, will remain on the Board.

Under Dr. Gorman's leadership, Neurocrine evolved into a fully integrated biopharmaceutical company with a robust pipeline and a strong financial standing. Notable achievements during his tenure include the commercial success of INGREZZA® (valbenazine), a treatment for tardive dyskinesia and chorea associated with Huntington's disease. Gorman's focus on addressing areas with limited treatment options has driven the company’s mission to discover and develop innovative medicines. Recently, Neurocrine submitted two New Drug Applications to the FDA for crinecerfont, aimed at treating classic congenital adrenal hyperplasia (CAH) in both adults and children. The company’s pipeline now boasts 17 clinical development programs targeting neurology, neuroendocrinology, and neuropsychology.

Reflecting on his time as CEO, Dr. Gorman expressed pride in Neurocrine’s accomplishments, highlighting the transformation from a clinical-stage company to one with a diverse pipeline and significant R&D capabilities. He emphasized the successful launch of INGREZZA and the ongoing efforts to prepare for crinecerfont’s potential market entry next year. Gorman affirmed his confidence in the company’s future and in Dr. Gano’s ability to lead the next phase of growth.

Dr. Gano, who has been with Neurocrine for over two decades, expressed his dedication to the company’s mission and vision. He emphasized the importance of continuing to develop treatments for patients with neurological disorders. Gano’s extensive experience in business development and strategic collaborations has been pivotal for Neurocrine. He was instrumental in developing partnerships with major pharmaceutical companies and led the acquisition of Diurnal Group Plc, which expanded Neurocrine's operations into the UK and EU. Gano also played a key role in the development of several FDA-approved medicines, including INGREZZA, ORILISSA®, and ORIAHNN®.

Board Chairman William H. Rastetter, Ph.D., thanked Gorman for his unwavering dedication and welcomed Gano as CEO-elect. Rastetter highlighted Gano’s broad expertise and clear vision, expressing confidence in his leadership to drive the company’s continued success.

Neurocrine Biosciences has a clear objective: to alleviate suffering by developing treatments for under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for various conditions and a strong pipeline of investigational compounds. With a commitment to innovative science, Neurocrine aims to provide life-changing therapies for patients in need.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!